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Occlusive Retinal Vasculitis Secondary to Sjogren’s Syndrome: A Case Report and
Review
Abstract
Background: To bring attention to the potential and serious ophthalmic sequalae of Sjogren’s syndrome,
specifically occlusive retinal vasculitis.
Case: A 70-year-old male patient without previous ocular pathology presented with acute onset, bilateral,
painless vision loss. Fundus evaluation revealed extensive retinal occlusive disease with bilateral disc
edema, cystoid macular edema, and diffuse phlebitis. The patient was admitted, received a full systemic
work-up and was carefully co-managed by ophthalmology, neurology, infectious disease, vascular surgery,
dermatology, rheumatology and medicine. Evaluation supported a leading diagnosis of Sjogren’s
syndrome associated vasculitis.
Conclusion: The patient underwent treatment with oral steroids and intravitreal injections of anti-vascular
endothelial growth factor; treatment successfully restored usable vision in one eye. This case will
highlight the importance of prompt and thorough evaluation of patients diagnosed with or with suspected
diagnosis of Sjogren’s syndrome since severe ocular manifestations can mirror severe, potentially lifethreatening, levels of systemic complications.
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INTRODUCTION
Sjogren’s syndrome (SS) is a progressive, systemic, autoimmune disease. It
primarily impacts the salivary and lacrimal glands thus resulting in xerostomia and
xerophthalmia. While this condition largely targets the aforenoted exocrine glands,
it has the potential to affect all organ systems through mechanisms of inflammation
and infiltration.1
The most commonly known ophthalmic manifestation of SS is
keratoconjunctivitis sicca. This is secondary to impaired tear secretion after
inflammatory infiltration of the lacrimal gland. Since ocular surface disease
associated with SS is extensively known and widely researched, this report will not
cover it in full detail. Additional SS anterior segment manifestations can include
filamentary keratitis, corneal infiltrates, conjunctivitis, corneal vascularization, and
opacification and scleritis.1 The lesser known ophthalmic manifestations, those
involving the posterior segment, can include retinitis, neuromyelitis optica,
ischemic optic neuropathy, phlebitis, and retinal detachment.2,3
This case report demonstrates how a severe and lesser-known ophthalmic
manifestation, occlusive retinal vasculitis, may be the first observable and
symptom-causing indication of SS. The diagnosis, co-management approach, and
treatment modalities will also be discussed. Lastly, the rapid timeline during which
drastic changes can occur will be presented to emphasize the importance of prompt
diagnosis and treatment for patients with SS complications.
CASE
A 70-year-old African American male presented with a chief complaint of
bilateral, sudden, painless, reduction of vision, right eye greater than left. Over the
course of the next several hours, vision in both eyes continued to deteriorate. Ocular
history was unremarkable as was family history of eye disease.
He denied jaw claudication, temporal scalp tenderness or malaise. Two-months
prior, the patient experienced acute left-sided facial swelling and was diagnosed
with a sinus infection. He completed a course of oral antibiotic prescribed by his
primary care physician. This resolved most symptoms, though he reported chronic
gingival tenderness since then and was referred to a dentist. Additionally, the
patient had noticed a pustular rash on his palms and soles of feet that evolved into
flat, dark rashes. He also developed arthritis-type swelling of his bilateral
phalangeal joints with symptoms that lasted for a few days and self-resolved. He
denied any genital lesions or tick exposure.
Medical history included hypertension, hyperlipidemia, hypothyroid,
osteoarthritis, benign prostate hyperplasia, chronic kidney disease (stage 3),
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thrombocytopenia, and colon cancer status post partial colectomy. His current
medications were baby aspirin, citalopram, tamsulosin, finasteride, levothyroxine,
amlodipine, and metoprolol. The patient had recent cardiac echocardiogram and
cardiac stress tests which were normal. Social history was negative for smoking,
alcohol, and drugs.
Entering visual acuity was 5/120 in the right eye (Feinbloom) and 20/400 in the
left (Snellen) with no improvement on pinhole or refraction. Ocular motilities were
full, pupil reaction appeared normal without presence of APD, slit lamp anterior
segment exam was unremarkable and intraocular pressures were normal.
Confrontation visual fields were markedly constricted in all quadrants in both eyes.
Dilated retinal examination and OCT of the disc and macula showed hyperemic,
edematous optic nerves with peripapillary retinal edema and pronounced macula
edema in both eyes. (See Figure 1).

Figure 1: OCT Macula & OCT Optic Disc Cube

Bilateral intraretinal hemorrhages were evident throughout the posterior pole and
mid-periphery with markedly attenuated retinal arteries and venous tortuosity, a
presentation consistent with bilateral central retinal vein occlusion. A cotton wool
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spot was noted at the left eye’s inferior arcade. Fundus appearance can be seen in
Figures 2 & 3. The patient’s blood pressure was taken and was 136/78 mm Hg.

Figures 2: Fundus Photos OD/OS

Figures 3: Red-Free Fundus Photos OD/OS

He was referred for an urgent retina specialist consultation. Given the unclear
etiology and severity of the patient’s bilateral vision loss it was recommended that
he be admitted to the hospital for further testing and observation. Table 1 lists the
tests ordered along with the respective results; initial lab work results were
significant only for elevated ESR and CRP.
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TEST
Complete Blood Count
Sed Rate
Week 1, Day 1
Week 2
Week 3
Week 4
Cholesterol panel
COAG Panel
C Reactive Protein
Week 1, Day 1
Week 2
Week 3
Week 4
ANA Titer
Rheumatoid Factor
Lyme C6
RPR, qualitative
Treponema Pallidum ABS
HIV
C-ANCA/P-ANCA
Toxoplasma Gondii
Bartonella Henselae/ Quintana
Mycoplasma Pneumoniae
Varicella Zoster
Herpes Simplex
NMO-IgG Auto Ab
Epstein-Barr Virus
Hepatitis B&C
QuantiFERON TB
Lupus (Russell Viper)
DS DNA Crithidia (SLE)
HLA B27
Angiotensin Converting enzyme
CPK
Homocysteine
Strongyloides
Schistosoma
Anti -scleroderma
Anti SS-A (Connective tissue disease: SLE, SS,
RhA)
Anti SS-B
HLA B51 (Behcet’s disease)
G6PD
Factor V Leiden
Protein S & C
Factor II Prothrombin, DNA
CSF

RESULT
Mild anemia
High (125 mm/hr)
High (55 mm/hr)
Normal (3 mm/hr)
Normal (5 mm/hr)
Normal
Normal
Positive
Negative
Negative
Negative
Positive
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Ab present - Immune
Negative
Negative
Negative
Negative
Negative
Negative
Normal
Negative
Negative
Normal
Normal
Negative
Negative
Negative
High
Normal
Positive
Normal
Negative
Normal
Negative
Negative: HSV, EBV, CMV, VZV, Fungus, Lyme,
ACE, VDRL Non-reactive, Gram stain (-), zero
oligoclonal bands

Table 1: Lab tests ordered and results
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A dermatology exam was normal except for the non-blanchable, maculopapular
rash on both hands and feet with multiple spots, radius ranging from 1-3 mm.
Because of the rash, infectious disease was consulted for a syphilis evaluation. An
infectious disease work-up showed syphilis, TB, HIV, Lyme, hepatitis, and
toxoplasmosis tests were all negative. A neurological exam was normal. Dentistry
was consulted; a biopsy of labial mucosa and minor salivary gland showed nonspecific, mild sialadenitis with lymphocytic aggregates. This corresponded to the
patient’s complaint of a general dry mouth (treatment was not initiated immediately
due to the urgency of systemic management). A rheumatology workup revealed
positive ANA and SS-A, raising the concern for SS, Systemic Lupus
Erythematosus (SLE) and Behchet’s disease. Additional SLE testing was negative.
Behcet’s was thought to be less likely because HLA-B51 was positive but no oral
or genital lesions were present (though it is possible the patient had both SS and
Behcet’s). IV steroids were initiated under the management of rheumatology with
the intention of initiating immunomodulatory therapy subsequently.
One week later, the patient returned for a retinal exam and fluorescein
angiography. A dilated retinal exam continued to show disc edema and hyperemia,
dilated tortuous veins, attenuated arteries with silver-wire appearance, scattered
dot/blot and flame hemorrhages and microaneurysms in both eyes; the cotton wool
spot on the inferior arcade OS persisted. The right eye’s retina had a new overall
whitening of the fundus grounds. There was no vitritis in either eye. Fundus
appearance can be seen in Figure 4.

Figures 4: Fundus Photography Collage OD/OS
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Fluorescein angiography demonstrated diffuse occlusive vasculitis with large
areas of capillary nonperfusion and vascular sheathing (right eye greater than left)
with bilateral central retinal vein occlusion. (See Figure 5).

Figures 5: Fluorescein Angiography OD/OS (Mid-phase)

Based on the marked change in fundus appearance and macular status, significant
progression had occurred over the past days. At this point, the patient had
completed his course of IV Solumedrol and was being treated with 80 mg
prednisone PO daily.
A few days later an RAPD of the right eye was noted along with mild anterior
vitritis (1+ cells), phlebitis and an increase in retinal hemorrhaging of the right eye
only. Retinal findings of the left eye were unchanged from the previous exam. A
treatment plan was made to initiate bilateral, intravitreal Avastin injections. The
patient was discharged from the hospital several days later and continued his course
of 80 mg prednisone PO.
After the first course of Avastin injections, vision was 2/200 (Snellen “E”) in the
right eye and improved to 20/70+2 in the left. At this time, no vitritis or cells were
noted. Optic disc edema was improving. OCT showed persistent bilateral macular
edema but with signs of improvement. Schirmer I test (without anesthetic) was
performed and was positive in the right eye according to the American College of
Rheumatology and European League Against Rheumatism (ACR/EULAR)
classification (4 mm in the right eye, 8 mm in the left) after five minutes. The patient
also had irregular ocular surface staining with sodium fluorescein and reduced
TBUT in both eyes. Rose Bengal staining was not performed.
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At the follow up, visual acuity was 2/200 (Snellen “E”) in the right eye and 20/40
in the left; vision had improved significantly in the left eye. OCT showed
improving bilateral macula edema. (See Figure 6). Fundus exam revealed
improving optic nerve edema and hemorrhages in both eyes. The patient received
a second round of intravitreal Avastin injections. He was also examined by a neuroophthalmologist. At this time, he continued treatment with 60 mg PO daily of
prednisone as per his taper by rheumatology.

Figures 6: OCT Macula OD/OS

Visual acuity two weeks later improved to 6/200 (Snellen “E”) in the right eye
and 20/30-2 in the left. Optic nerve pallor was noted in the right eye more than the
left and some resolution of retinal hemorrhaging was noted in both eyes. The patient
received his third course of Avastin injections. OCT revealed near resolution of
macular edema with both maculae appearing relatively flat with minimal
intraretinal fluid. (See Figure 7). Unfortunately, two months later the patient passed
away and the exact cause was not identified. For a timeline of major points of the
case see Figure 8.
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Figure 7: OCT Macula OD/OS

Figure 8: Case Report Timeline
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After an exhaustive systemic work-up, infectious, and neurologic causes for the
patient’s retinal presentation were ruled out. Initially CRP was positive and ESR
was elevated, both trended downward after initiation of steroid therapies. The only
labs to return positive results were the ANA, SSA, and HLA-B51 which could
indicate SS or Behcet’s syndrome (or both) as possible autoimmune etiologies.
Rheumatology ultimately diagnosed SS given the absence of oral or genital lesions
typically associated with Behcet’s. Additionally, the patient’s symptomatic dry
mouth and evidence of dry eye lent themselves to a diagnosis of SS. Lip biopsy
showed lymphocytic sialadenitis. There was no salivary analysis performed.
According to the ACR/EULAR classification, there was enough evidence to
warrant the SS diagnosis. Despite the history of palmar/ plantar rash which may
have been a dermatologic representation of vasculitis from SS, no biopsy was
performed due to significant resolution post-steroid therapy. Therefore, a diagnosis
of cutaneous vasculitis versus hypersensitivity to ASA treatment or other causative
agents was not definitively made.
DISCUSSION
Sjogren’s Syndrome currently affects roughly 1 to 2 million people in the United
States. It is more common in females, accounting for approximately 93% of cases,
and the mean age of onset is 53 years old. SS is multifactored in causation; a
combination of genetic predisposition, environmental influence and hormonal
effects.4 Primary Sjogren’s syndrome (pSS) is diagnosed when the condition is
present without an underlying autoimmune disease. Secondary Sjogren’s syndrome
(sSS) is diagnosed when the condition is associated with a known, underlying
autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis,
polyarteritis nodosa, etc.).1 SS is also associated with a higher incidence of
lymphoproliferative disease and malignancy; the risk of lymphoma is 40 times
greater in SS patients than the general population.4-5
The histochemical basis for tissue damage secondary to SS lies in defective
immune responses and inappropriate activation of the inflammatory cascade.
Autoreactive T-cells along with autoreactive and hyper-reactive B-cells are present.
Epithelial cells seem to be the hub of irregular cytokine and chemokine production
playing a major role in the faulty immune activation process. The resulting
autoimmune epithelitis can occur in any organ system.6 Systemic manifestations of
SS include cardiomyopathy, arthralgia, gastrointestinal disease, pulmonary disease,
cutaneous vasculitis and purpura, peripheral neuropathy, lymphadenopathy, and
renal disease.2,4
The diagnosis of SS is established based upon a combination of laboratory testing
and evaluation of xerophthalmia and xerostomia. Laboratory testing includes
antinuclear antibody (ANA), anti-SSA autoantigen, anti- SSB autoantigen and
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rheumatoid factor (RF). ANA positivity in SS ranges from 55 to 97%, anti-SSA
positivity in SS ranges from 16 to 70%, anti-SSB positivity ranges from 7 to 50%,
and RF positively ranges from 32 to 90%. Anti-SSA and anti-SSB antigens are not
specific to SS since they can be present in patients with other autoimmune
conditions and, occasionally, in healthy people. Xerophthalmia is diagnosed
utilizing Shirmer tear testing and rose bengal staining. Xerostomia is detected by
saliva collection, sialography, scintigraphy and sometimes lip biopsy.4 Skin biopsy
is often performed for vasculitis diagnosis if rash or purpura is present and often
identifies leukocytoclastic or lymphocytic vasculitis. Cutaneous vasculitis of this
type has been identified in up to 60% of SS patients.2
A consensus on formal criteria for SS diagnosis was made in 2016 by the
ACR/EULAR.7 The diagnosis is based on a weighted score of the following 5
items: positive anti-SSA(Ro) antibody, positive lymphocytic sialadenitis, abnormal
ocular surface staining score, a Schirmer test less than or equal to 5 mm in 5
minutes, and an unstimulated salivary flow rate less than or equal to 0.1mL/min.
The first two factors are assigned scores of 3 points each, while the following three
factors are assigned 1 point each. A total score of greater than or equal to 4 meets
the criteria for SS. The sensitivity and specificity in the detection of SS using this
system were 96% and 95% respectively.8,9
Vasculitis in Sjogren’s Syndrome
Vasculitis secondary to SS is due to irregular deposition of immune complexes;
this is a rather uncommon extraglandular complication that can be severe. The
reported prevalence of Sjogren’s-associated vasculitis is 5-32%.3 There are two
classes of systemic vasculitis that can occur secondary to SS: small-vessel and
medium-large vessel. Small-vessel vasculitis is immune-complex mediated and can
be subcategorized as either cryoglobulinemic vasculitis or anti-neutrophil
cytoplasmic antibody (ANCA)-associated vasculitis. The former is the most
commonly presenting vasculitis associated with SS and involves cryoglobulins
(monoclonal immunoglobulins) that are over stimulated by autoantigens. Mediumlarge vessel vasculitis can be acute and necrotizing, often presenting with a purpura
like that of polyarteritis nodosa.6 Small vessel vasculitis accounts for approximately
5% of Sjogren’s vasculitis and most commonly presents as skin rash or purpura.
Eighty eight percent of cutaneous lesions present as purpura (palpable or nonpalpable) of the lower limbs or urticariform macules in the upper extremities, face
or trunk.9
Cutaneous vasculitis associated with SS is a notable finding because it is a
predictor of more severe disease and comorbidities (including arthritis, peripheral
neuropathy, glomerulonephritis, and increased hospitalizations). Sjogren’s
vasculitis can also cause secondary peripheral neuropathy and neuromyelitis optica,
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also known as Devic’s disease. The latter is a complication involving an
autoimmune inflammatory attack of the optic nerve and can often be mistaken for
multiple sclerosis.3
Cases of retinal vasculitis associated with SS have been noted, albeit they are rare.
Wanatabe et al. reported a case of SS-associated retinal vasculitis similar to ours: a
49-year-old man who presented with dry mouth, rash on the skin of the hands and
legs and bilateral visual disturbances. Retinal exam revealed bilateral intra and preretinal hemorrhages, exudates, and vascular sheathing and extensive areas of
vascular non-perfusion on fluorescein angiography. Skin biopsy was performed
along with the systemic work-up. Anti-SSA and anti-SSB antibodies were positive,
while ANA, anti-dsDNA antibodies and ANCA were negative. Parotid
scintigraphy demonstrated hypofunction. The patient was eventually diagnosed
with small-vessel retinal and cutaneous vasculitis secondary to SS. Treatment
included oral prednisone and pan retinal photocoagulation (PRP) which gradually
improved the patient’s presentation and symptoms.10
Farmer et al. reported two cases of females with severe bilateral retinal vasculitis
associated with SS. Both had autoantibodies against SSA antigen and mild systemic
signs of the disease. Like Wanatabe’s case report, treatment included a course of
systemic steroid therapy and PRP. Unlike the previous case, however, the therapy
course did little to remedy the severe ophthalmic impact of the disease; both
patients suffered progressive, irreversible vison loss from extensive retinal
ischemia, neovascularization of the optic disc, retina and anterior segment and
ultimately tractional retinal detachment.11
When we consider the aforenoted cases established in the literature along with the
case at hand, similarities can be identified. Firstly, the initial complaint and
presentation of sudden, bilateral, severe vision loss and secondarily, the initial
fundus presentation that was already at a severe stage of retinal disease. The
presence of cutaneous lesions and systemic work-up results varied among cases,
however, incongruous systemic features are rather typical of SS patients and
autoimmune conditions in general. All cases were treated with systemic steroids
and retinal intervention (either PRP or anti-VEGF) to reduce vascular proliferation.
Treatment Options
SS treatment options are determined based on the disease manifestation and
extent. In treating xerophthalmia, topical anti-inflammatory agents (cyclosporine
A) are a mainstay along with tear replacement therapy. Xerostomia treatment
includes salivary stimulation and replacement therapy and treatment of
complications such as increased frequency of dental carries. Muscarinic agonist
agents administered orally (pilocarpine and cevimeline) have been shown to
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improve ocular signs and symptoms of keratoconjunctivis sicca and reduce
symptomatic oral dryness. Systemic complications of SS are managed with antiinflammatories (steroids and NSAIDS) and research has supported use of immune
modulator, antimalarial (hydroxychloroquine) and monoclonal antibody
(Rituximab) therapy.4
Because of the wide range and variety of SS manifestations, a multi-specialty team
is often required for proper diagnosis and treatment. As seen in this case report, the
team can include ophthalmology, neurology, infectious disease, rheumatology,
vascular surgery, dermatology, and internal medicine.
CONCLUSION
Eyecare practitioners are aware of Sjogren’s syndrome’s proclivity for producing
inflammation in the salivary and lacrimal glands. However, the autoimmune
response from this disease can also cause extraglandular inflammation leading to
potentially sight-threatening complications as well as serious systemic
implications. This case reminds clinicians to remain vigilant for ocular
manifestations, since they can range from ocular surface disease to disorders of the
optic nerve and retina, in this case a rare instance of occlusive retinal vasculitis.
The presence of these ocular signs warrants prompt evaluation of patients with
suspected Sjogren’s syndrome in order to effectively initiate systemic treatment and
mitigate potentially life-threatening sequalae.
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